Our study took steps to explore effects of lifelong propensity to a particular sleep pattern on breast cancer mortality in subgroups of women on different treatments and observed some evidence that women with (lifelong) insomnia symptoms and ER + /PR + had increased survival if they received no chemotherapy or aromatase inhibitors, compared to women on other chemotherapy. The gene discussed is CYP19A1; the disease is insomnia measurement.